Page last updated: 2024-09-03

3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and amphetamine

3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide has been researched along with amphetamine in 1 studies

Compound Research Comparison

Studies
(3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide)
Trials
(3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide)
Recent Studies (post-2010)
(3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide)
Studies
(amphetamine)
Trials
(amphetamine)
Recent Studies (post-2010) (amphetamine)
140613,0713291,977

Protein Interaction Comparison

ProteinTaxonomy3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide (IC50)amphetamine (IC50)
Phenylethanolamine N-methyltransferaseBos taurus (cattle)0.96
Cytochrome P450 2A6Homo sapiens (human)3.5
Cytochrome P450 2A5Mus musculus (house mouse)2.85
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.96
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)0.96

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beyaert, MG; Daya, RP; Dyck, BA; Johnson, RL; Mishra, RK1

Other Studies

1 other study(ies) available for 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and amphetamine

ArticleYear
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:3

    Topics: Allosteric Regulation; Amphetamine; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Male; Motor Activity; Neostriatum; Nucleus Accumbens; Prefrontal Cortex; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia

2013